

## Crossed \$1 Billion mark

02 July 2015 | Analysis | By BioSpectrum Bureau

### Crossed \$1 Billion mark



#### Singapore:

##### **Dr Reddy's Laboratories, India**

**Chairman:** Mr Satish Reddy

**Revenue:** \$2273.4MN

**Business:** Produces and markets finished dosage forms, active ingredients and biosimilar products

Clocking an annual growth of 12 percent, Dr Reddy's Laboratories is India's second largest drugmaker by sales. The company has strong presence in generic markets across the globe and has 21 manufacturing facilities and 9 API manufacturing units. Last fiscal year, Dr Reddy's invested heavily in research and development, increasing its focus on biosimilars and proprietary products. The company had filed three NDAs for Proprietary Products last year with the regulatory authorities.

In a bid to further strengthen its presence in dermatology, respiratory and pediatrics segments, Dr Reddy's announced the acquisition of select portfolio of established product business of UCB in India, Nepal, Sri Lanka and Maldives for Rs 800 crore.

The company indicated that it is all set to expand the capacity of three of its bulk drugs and intermediates manufacturing plants located in Telangana, India, with a combined investment of Rs 82 crore. Dr Reddy's Custom Pharmaceutical Services division expanded its existing custom service facilities with a new formulation development laboratory in Miyapur, Hyderabad.

Among other major approvals last year, the drugmaker announced the approval and launch of generic version of Roche's blockbuster drug Valcyte. The company also announced the launch of Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of TAXOTERE (docetaxel Injection) in the US market.